Tagged with china

China Gaobo Zhou is Partner and co-leader of the Healthcare Practice in China and has been with McKinsey for over a decade, Gaobo discusses the changes occurring within the complex and fast-paced Chinese healthcare landscape over the past few years and how McKinsey supports industry stakeholders in China to help them…

Mental Health “Mental health is currently a major problem in China, and will become an ever greater problem unless effective interventions are put in place.”   Mental Health has Long Been a Serious Problem in China   The most populous nation in the world is said by some to be “in the…

Sanofi Pius Hornstein, Country Chair of Sanofi China appointed in March 2019, shares his initial impressions on the fast-changing Chinese market; his mandate to drive a transformation of the organization in line with their mid- to long-term strategy; his priorities of launching a new portfolio, building up the organization, and spearheading…

China HE Ming, founder and CEO of Sino-American (Suzhou) Pharmaceutical Services (SAPS), shares his commitment to bringing international quality standards to the Chinese pharma industry, the comprehensive portfolio of quality management, verification and compliance services SAPS offers to the pharma, biotech and medical device industries in China and the US, as…

China Dr Shuqian Jing, founder, Chairman and CEO of Gmax Biopharm, an innovative biotech company headquartered in Hangzhou, shares how his experiences at global biopharma companies like BMS and Amgen inspired him to create his own biotech company; Gmax’s focus on G protein-coupled receptor (GPCR) therapeutic antibodies; the exciting pipeline the…

China Serial entrepreneur and Ronnsi CEO Yiming Yao discusses the inspiration behind the company’s formation, its unique specialization in ovine heparin, and his strategy to take the firm to the next level globally.   Currently, I believe that we might be the only company in the world working in the area…

Biotech China’s rapidly-growing biotech sector is increasingly hungry for preclinical drug candidates to commercialise in China, and Chinese companies are spending top dollar for cutting-edge technology from the US and UK. Despite mounting US-China tensions in the life sciences, the demand remains strong for cross-border licensing deals, which are raising drug…

China Dr Dafang Zhong, director of Shanghai Center for Drug Metabolism and Pharmacokinetics Research at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, shares his professional career within the DMPK space, as well as the important work that the Center has done in contributing to the growth and development…

USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry.   Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…

China Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it is today, the contributions of Zambon China to the Group’s overall growth, the importance of people and organization development, renewable…

China Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in China with both bio-analytical and clinical services, their close collaborations with key hospitals, and their ‘Two Countries, One System’ philosophy…

China Dr Jiang Lei and Dr Shou Jianyong, EnnovaBio’s co-founders, introduce their strategy and outline the progress being made in the Chinese biopharma industry at large.   We are a Chinese company so we really want to benefit Chinese patients and meet unmet medical needs in China. Otherwise, why would we…